Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EVA1C pseudogene 2 (EVA1CP2) is annotated as a pseudogene, meaning it is a genomic DNA sequence resembling a gene but typically lacking the ability to code for a functional protein. There is no evidence EVA1CP2 is a receptor, enzyme, transporter, or druggable target. Most available information and associated biological functions refer to the EVA1C protein (Eva-1 homolog C), which is a transmembrane protein involved in axon guidance, immune cell infiltration, and possibly certain disease conditions, not to EVA1CP2. No functional, disease, or drug data exist specifically for EVA1CP2 in the scientific literature or gene databases. EVA1CP2 is classified as a pseudogene, not an active or functional gene. There is no evidence that EVA1CP2 produces a functional protein or plays a role as a therapeutic target. This target is likely inappropriate for therapeutic or pharmacological research purposes due to its annotation as a pseudogene. All available disease, functional, or pharmacological data refer to the actual EVA1C gene/protein, not the pseudogene EVA1CP2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on EVA1C pseudogene 2 (EVA1CP2).